110 related articles for article (PubMed ID: 15672606)
41. Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display.
Coomber DW; Ward RL
Clin Cancer Res; 2001 Sep; 7(9):2802-8. PubMed ID: 11555596
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibodies against different epitopes of nonstructural protein sigmaNS of avian reovirus S1133.
Hou HS; Su YP; Shieh HK; Lee LH
Virology; 2001 Mar; 282(1):168-75. PubMed ID: 11259199
[TBL] [Abstract][Full Text] [Related]
43. Identification of an epitope of tumor necrosis factor (TNF)-receptor type 1 (p55) recognized by a TNF-alpha-antagonist monoclonal antibody.
Corti A; Bagnasco L; Cassani G
Lymphokine Cytokine Res; 1994 Jun; 13(3):183-90. PubMed ID: 7524695
[TBL] [Abstract][Full Text] [Related]
44. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
[TBL] [Abstract][Full Text] [Related]
45. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
[TBL] [Abstract][Full Text] [Related]
46. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii.
Burns JM; Majarian WR; Young JF; Daly TM; Long CA
J Immunol; 1989 Oct; 143(8):2670-6. PubMed ID: 2477452
[TBL] [Abstract][Full Text] [Related]
47. Generation and characterization of monoclonal antibodies to the human thyrotropin (TSH) receptor: antibodies can bind to discrete conformational or linear epitopes and block TSH binding.
Seetharamaiah GS; Wagle NM; Morris JC; Prabhakar BS
Endocrinology; 1995 Jul; 136(7):2817-24. PubMed ID: 7540542
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine.
Hwang LA; Phang BH; Liew OW; Iqbal J; Koh XH; Koh XY; Othman R; Xue Y; Richards AM; Lane DP; Sabapathy K
Cell Rep; 2018 Jan; 22(1):299-312. PubMed ID: 29298430
[TBL] [Abstract][Full Text] [Related]
49. Generation of recombinant metapneumovirus nucleocapsid protein as nucleocapsid-like particles and development of virus-specific monoclonal antibodies.
Petraitytė-Burneikienė R; Nalivaiko K; Lasickienė R; Firantienė R; Emužytė R; Sasnauskas K; Zvirblienė A
Virus Res; 2011 Nov; 161(2):131-9. PubMed ID: 21827798
[TBL] [Abstract][Full Text] [Related]
50. Epitope mapping of two major inhalant allergens, Der p I and Der f I, from mites of the genus Dermatophagoides.
Chapman MD; Heymann PW; Platts-Mills TA
J Immunol; 1987 Sep; 139(5):1479-84. PubMed ID: 2442247
[TBL] [Abstract][Full Text] [Related]
51. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay.
Pospísilová S; Brázda V; Amrichová J; Kamermeierová R; Palecek E; Vojtesek B
J Immunol Methods; 2000 Apr; 237(1-2):51-64. PubMed ID: 10725451
[TBL] [Abstract][Full Text] [Related]
52. Idiotypic immunization induces immunity to mutated p53 and tumor rejection.
Ruiz PJ; Wolkowicz R; Waisman A; Hirschberg DL; Carmi P; Erez N; Garren H; Herkel J; Karpuj M; Steinman L; Rotter V; Cohen IR
Nat Med; 1998 Jun; 4(6):710-2. PubMed ID: 9623981
[TBL] [Abstract][Full Text] [Related]
53. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus.
Wolkowicz R; Peled A; Elkind NB; Rotter V
Cancer Detect Prev; 1998; 22(1):1-13. PubMed ID: 9466043
[TBL] [Abstract][Full Text] [Related]
54. [Monoclonal antibodies against human secretory component: epitope specificity and utility for immunoanalysis].
Griazeva IV; Samoĭlovich MP; Klimovich BV; Pavlova MS; Vartanian NL; Kirienko AN; Klimovich VB
Zh Mikrobiol Epidemiol Immunobiol; 2010; (4):54-9. PubMed ID: 20795387
[TBL] [Abstract][Full Text] [Related]
55. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library.
Stephen CW; Lane DP
J Mol Biol; 1992 Jun; 225(3):577-83. PubMed ID: 1376364
[TBL] [Abstract][Full Text] [Related]
56. Understanding p53 functions through p53 antibodies.
Sabapathy K; Lane DP
J Mol Cell Biol; 2019 Apr; 11(4):317-329. PubMed ID: 30907951
[TBL] [Abstract][Full Text] [Related]
57. Simultaneous and label-free determination of wild-type and mutant p53 at a single surface plasmon resonance chip preimmobilized with consensus DNA and monoclonal antibody.
Wang Y; Zhu X; Wu M; Xia N; Wang J; Zhou F
Anal Chem; 2009 Oct; 81(20):8441-6. PubMed ID: 19772286
[TBL] [Abstract][Full Text] [Related]
58. Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.
Brandt-Rauf PW; Monaco R; Pincus MR
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9262-6. PubMed ID: 7937752
[TBL] [Abstract][Full Text] [Related]
59. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins.
Prodinger WM; Hellwage J; Spruth M; Dierich MP; Zipfel PF
Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):41-7. PubMed ID: 9512460
[TBL] [Abstract][Full Text] [Related]
60. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon JV; Greaves R; Iggo R; Lane DP
EMBO J; 1990 May; 9(5):1595-602. PubMed ID: 1691710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
